Lombard Medical, Inc. operates as a medical technology company. It engages in the development, manufacture, and marketing of endovascular stent-grafts that address significant unmet needs in the repair of aortic aneurysms. The company was founded on January 16, 2014 and is headquartered in Didcot, the United Kingdom.
![Lombard Medical logo](https://files.capedge.com/F-1A/0001193125-14-122531/g653540g23q36.jpg)
Company profile
Ticker
EVARF
Exchange
Website
CEO
Kurt Bloch Lemvigh
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Latest filings (excl ownership)
6-K
Current report (foreign)
26 Apr 18
6-K
Current report (foreign)
7 Mar 18
6-K
Current report (foreign)
17 Jan 18
6-K
Current report (foreign)
12 Jan 18
25
Voluntary exchange delisting
9 Nov 17
6-K
Lombard Medical Reports First Half and Third Quarter 2017 Financial Results
31 Oct 17
6-K
Lombard Medical Announces Shares to Trade on OTCQX
30 Oct 17
6-K
Current report (foreign)
19 Oct 17
6-K
Current report (foreign)
10 Oct 17
6-K
Lombard Medical’s New Delivery System for Aorfix™ Endovascular Aortic Aneurysm Repair System Launched in Japan
26 Sep 17
Latest ownership filings
SC 13D/A
Beneficial ownership report (amended)
11 Apr 17
SC 13G/A
Lombard Medical, Inc.
7 Feb 17
SC 13D/A
Lombard Medical, Inc.
23 Jan 17
SC 13D
Beneficial ownership report
28 Dec 16
SC 13D
Beneficial ownership report
28 Dec 16
SC 13D/A
Beneficial ownership report (amended)
15 Sep 16
SC 13D/A
Beneficial ownership report (amended)
18 Apr 16
SC 13G/A
Lombard Medical, Inc.
12 Feb 16
SC 13G/A
Beneficial ownership report (amended)
5 Feb 16
SC 13G
Beneficial ownership report
22 Jan 16